NEWS

News Articles

CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent

January 13, 2022

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat patient suffering from Alzheimer’s: “The announcement by CMS sets a dangerous and far-reaching precedent for…

Read More

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

January 11, 2022

ATLANTA, GA, January 11, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with…

Read More

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

January 7, 2022

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases. The pair announced the deal Thursday morning, which includes $50 million upfront for the initial five program, with an option to collaborate on five more. Amgen will pay…

Read More

GEORGIA TREND NAMES MARIA THACKER GOETHE AS ONE OF THE “100 MOST INFLUENTIAL GEORGIANS” IN 2022

January 6, 2022

ATLANTA, GA – Georgia Trend Magazine named Maria Thacker Goethe, Chief Executive Officer at Center for Global Health Innovation (The Center) and President & CEO of Georgia Bio, as one of the 100 Most Influential Georgians in 2022 for her work advancing Georgia as a top bioscience and MedTech hub. The Center just announced the…

Read More

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

January 6, 2022

– Expands Amneal’s Neurology Presence into Spasticity Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology…

Read More

Strados Labs, Growing Medtech Company, Raises $4.5M in Pre-series A Funding Round

January 6, 2022

Funding to fuel next key milestones as company continues to target asthma, COPD and infectious respiratory diseases in 2022 Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, today announced its pre-series A round of funding at $4.5M. Investors…

Read More